Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome

Bibliography

• Stewart WF, Liberman JN, Sandler RS, Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol 1999;94:3530-40
   PubMed Web of Science ®Google Scholar
• Drossman DA, Li Z, Andruzzi E, U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993;38:1569-80
   PubMed Web of Science ®Google Scholar
• Singh G, Lingala V, Wang H, Use of health care resources and the cost of care for adults with constipation. Clin Gastroenterol Hepatol 2007;5:1053-8
   PubMed Web of Science ®Google Scholar
• Irvine EJ, Ferrazzi S, Pare P, Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol 2002;97:1986-93
   PubMed Web of Science ®Google Scholar
• Pare P, Ferrazzi S, Thompson WG, An epidemiological survey of constipation in canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001;96:3130-7
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Thompson WG, Chey WD, Functional bowel disorders. Gastroenterology 2006;130:1480-91
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Thompson WG, Chey WD, In: Drossman DA, Corazziari E, Delvaux M, editors. Rome III: the functional gastrointestinal disorders. 1st edition. Degnon Associates; McLean, VA: 2006. p. 487-555
   Google Scholar
• Camilleri M, Bharucha AE, Ueno R, Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006;290:G942-7
   PubMed Web of Science ®Google Scholar
• Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation; a double-blind placebo-controlled, dose ranging study to evaluate safety and efficacy. Aliment Pharmacol Ther 2007;25:1351-61
   PubMed Web of Science ®Google Scholar
• Bassil AK, Borman RA, Jarvie EM, Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Phamacol 2008;154:126-35
   PubMed Web of Science ®Google Scholar
• Jentsch TJ. CLC chloride channels and transporters: from genes to protein structure, pathology and physiology. Crit Rev Biochem Mol Biol 2008;43:3-36
   PubMed Web of Science ®Google Scholar
• Chey WD, Maneerattaporn M, Saad R. Pharmacologic and complimentary and alternative medicine therapies for irritable bowel syndrome. Gut Liver 2011;5:253-66
   PubMed Web of Science ®Google Scholar
• Moeser AJ, Haskell MM, Shifflett DE, ClC-2 chloride secretion mediates prostaglandin-induced recovery of barrier function in ischemia-injured porcine ileum. Gastroenterology 2004;127:802-15
   PubMed Web of Science ®Google Scholar
• Moeser A, Nighot P, Roerig B, Comparison of the chloride channel activator lubiprostone and the oral laxative Polyethylene Glycol 3350 on mucosal barrier repair in ischemic-injured porcine intestine. World J Gastroenterol 2008;14:6012-17
   PubMed Web of Science ®Google Scholar
• Moeser AJ, Nighot PK, Engelke KJ, Recovery of mucosal barrier function in ichemic porcine ileum and colon is stimulated by a novel agonist of the CID-2 chloride channel, lubiprostone. Am J Physiol Gastrointestinal Liver Physiol 2007;292:G647-56
   PubMed Web of Science ®Google Scholar
• Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral drug delivery of lipophilic drugs. Biomed Phamacother 2004;58:173-82
   PubMed Web of Science ®Google Scholar
• Mizumori M, Akiba Y, Kaunitz JD. Lubiprostone stimulates duodenal bicarbonate secretion in rats. Dig Dis Sci 2009;54:2063-9
   PubMed Web of Science ®Google Scholar
• Amitiza (lubiprostone) package insert. Sucampo Pharmaceuticals, Inc; Bethesda, MD: 2009
   Google Scholar
• Johanson JF, Drossman DA, Panas R, Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008;27:685-96
   PubMed Web of Science ®Google Scholar
• Barish CF, Drossman D, Johanson J, Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dig Sci 2010;55:1090-7
   PubMed Web of Science ®Google Scholar
• Schey R, Rao SS. Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome. Dig Dis Sci 2011;56:1619-25
   PubMed Web of Science ®Google Scholar
• Drossman DA, Chey WD, Johanson JF, Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome—results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29:329-41
   PubMed Web of Science ®Google Scholar
• Lembo A, Johanson J, Parkman H, Long-Term safety and effectiveness of lubiprostone, a chloride channel (CID-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci 2011;56:2639-45
   PubMed Web of Science ®Google Scholar
• Fokudo S, Hongo M, Kaneko H, Efficacy and safty of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Neurogastroenterol Motil 2011;23:544-e205
   PubMed Web of Science ®Google Scholar
• Chey WD, Drossman DA, Johanson JF, Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2012;35:587-99
   PubMed Web of Science ®Google Scholar
• Bassil AK, Borman RA, Jarvie EM, Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol 2008;154:126-35
   PubMed Web of Science ®Google Scholar
• Camilleri M, Gorman H. Intestinal permeability and irritable bowel syndrome. Neurogastroenterol Motil 2007;19:545-52
   PubMed Web of Science ®Google Scholar
• FDA Center for Drug Evaluation and Research (CDER)-2008
   Google Scholar
• Lisle R, Mueller R, Roach E. Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype. BMC Gastroenterol 2010;10:107
   PubMedGoogle Scholar
• MacDonald K, McKenzie K, Henderson M, Lubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice. Am J Physiol Lung Cell Mol Physiol 2008;295:L933-40
   Google Scholar
• Kapoor S. Lubiprostone: clinical applications beyond constipation. World J Gastroenterol 2009;15(9):1147
   PubMed Web of Science ®Google Scholar
• Lackner J, Jaccard J, Baum C, Patient-reported outcomes for irritable bowel syndrome are associated with patients' severity ratings of gastrointestinal symptoms and psychological factors. Clin Gastroenterol Hepatol 2011;9:957-64
   PubMed Web of Science ®Google Scholar